Using Extended-Release Injectable Aripiprazole for the Successful Treatment of Depressive Symptoms in Bipolar I Disorder
Joint Authors
Source
Issue
Vol. 2020, Issue 2020 (31 Dec. 2020), pp.1-2, 2 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2020-02-21
Country of Publication
Egypt
No. of Pages
2
Main Subjects
Abstract EN
Extended-release injectable (ERI) aripiprazole is indicated for schizophrenia and maintenance monotherapy of bipolar I disorder.
Clinical trials of aripiprazole failed to exhibit efficacy in the treatment of bipolar depression.
It has been suggested that relatively high doses, rapid titration of dose, a high dropout rate, and a high placebo effect might be the reasons of its ineffectiveness.
Here, we report a case of a 39-year-old woman with bipolar depression who was successfully treated with ERI aripiprazole.
American Psychological Association (APA)
Kuo, Joseph& Lin, Shih-Ku. 2020. Using Extended-Release Injectable Aripiprazole for the Successful Treatment of Depressive Symptoms in Bipolar I Disorder. Case Reports in Psychiatry،Vol. 2020, no. 2020, pp.1-2.
https://search.emarefa.net/detail/BIM-1150891
Modern Language Association (MLA)
Kuo, Joseph& Lin, Shih-Ku. Using Extended-Release Injectable Aripiprazole for the Successful Treatment of Depressive Symptoms in Bipolar I Disorder. Case Reports in Psychiatry No. 2020 (2020), pp.1-2.
https://search.emarefa.net/detail/BIM-1150891
American Medical Association (AMA)
Kuo, Joseph& Lin, Shih-Ku. Using Extended-Release Injectable Aripiprazole for the Successful Treatment of Depressive Symptoms in Bipolar I Disorder. Case Reports in Psychiatry. 2020. Vol. 2020, no. 2020, pp.1-2.
https://search.emarefa.net/detail/BIM-1150891
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1150891
